Menu
合作咨询 请在下方提供您的详细信息,以便我们了解您的需求和问题
您的称呼
电子邮件
联系方式
详细描述
荣誉资质
我们会定期发布一些关于医药的优秀文章,让您对我们有更深入的了解
2018室间质评-BRAF(组织样本)-白泽检验所
2018室间质评-EGFR(组织样本)-白泽检验所
2018室间质评-KRAS(组织样本)-白泽检验所
2018室间质评-流式细胞术(淋巴细胞亚群)-白泽检验所
白泽检验所营业执照-副本-最新版
白泽检验所医疗机构执业许可证
白泽检验所(临床基因扩增实验室资质)
白泽检验所(上海市病原微生物二级实验室备案证)
战略合作
我们会定期发布一些关于医药的优秀文章,让您对我们有更深入的了解
知识产权
我们会定期发布一些关于医药的优秀文章,让您对我们有更深入的了解
专利:
已受理 7 项(CTC 技术专利 5 项,cfDNA 标准品专利 1 项,基因检测专利 1 项);
人才项目:

上海市经信委项目(基于健康大数据的肿瘤智慧精准医疗应用系统研究);

上海市科委启明星项目(TCR 免疫分析在细胞治疗中的应用探索);

SCI 论文

YE Z L, DING Y M, CHEN Z, LI Z, MA S, XU Z H, CHENG L, WANG X Y, ZHANG X X, DING N, ZHANG Q, QIAN Q J. Detecting and phenotyping of aneuploidcirculating tumor cells in patients with various malignancies [J]. Cancer Biol Ther, 2019, 20(4): 546-51.

Zhu, L N, WU R J,YE Z L, et al. "Identification of two novel TPK1 gene mutations in a Chinese patient with thiamine pyrophosphokinase deficiency undergoing wholeexome sequencing" Journal of Pediatric Endocrinology and Metabolism, 32.3 (2019): 295-300. Retrieved 13 Jun. 2019, from doi:10.1515/jpem-2018-0363

YE Z L, QIAN Q M, JIN H J, QIAN Q J. Cancer vaccine: learning lessons from immune checkpoint inhibitors [J]. J Cancer, 2018, 9(2): 263-8.

LV S Q, YE Z L, LIU P Y, HUANG Y, LI L F, LIU H, ZHU H L, JIN H J, QIAN Q J. 11R-P53 and GM-CSF Expressing Oncolytic Adenovirus Target Cancer Stem Cellswith Enhanced Synergistic Activity [J]. J Cancer, 2017, 8(2): 199-206.

XU J Y, YE Z L, JIANG D Q, HE J C, DING Y M, LI L F, LV S Q, WANG Y, JIN H J, QIAN Q J. Mesothelin-targeting chimeric antigen receptor-modified T cells bypiggyBac transposon system suppress the growth of bile duct carcinoma [J]. Tumor Biol, 2017, 39(4): 11.

XU J Y, YE Z L, JIANG D Q, HE J C, DING Y M, LI L F, LV S Q, WANG Y, JIN H J, QIAN Q J. Mesothelin-targeting chimeric antigen receptor-modified T cells bypiggyBac transposon system suppress the growth of bile duct carcinoma [J]. Tumor Biol, 2017, 39(4): 11.

XU J Y, YE Z L, JIANG D Q, HE J C, DING Y M, LI L F, LV S Q, WANG Y, JIN H J, QIAN Q J. Mesothelin-targeting chimeric antigen receptor-modified T cells bypiggyBac transposon system suppress the growth of bile duct carcinoma [J]. Tumor Biol, 2017, 39(4): 11.

XU J Y, YE Z L, JIANG D Q, HE J C, DING Y M, LI L F, LV S Q, WANG Y, JIN H J, QIAN Q J. Mesothelin-targeting chimeric antigen receptor-modified T cells bypiggyBac transposon system suppress the growth of bile duct carcinoma [J]. Tumor Biol, 2017, 39(4): 11.